CALT vs. ICPT, TVTX, ENTA, OMER, NGM, APLS, RNA, CRNX, IMVT, and ACLX
Should you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Intercept Pharmaceuticals (ICPT), Travere Therapeutics (TVTX), Enanta Pharmaceuticals (ENTA), Omeros (OMER), NGM Biopharmaceuticals (NGM), Apellis Pharmaceuticals (APLS), Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), and Arcellx (ACLX). These companies are all part of the "medical" sector.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking.
Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.
In the previous week, Calliditas Therapeutics AB (publ) had 8 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 8 mentions for Calliditas Therapeutics AB (publ) and 0 mentions for Intercept Pharmaceuticals. Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.60 beat Intercept Pharmaceuticals' score of 0.30 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the media.
Intercept Pharmaceuticals has higher revenue and earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Intercept Pharmaceuticals has a net margin of -19.39% compared to Calliditas Therapeutics AB (publ)'s net margin of -40.19%. Intercept Pharmaceuticals' return on equity of -77.48% beat Calliditas Therapeutics AB (publ)'s return on equity.
Calliditas Therapeutics AB (publ) presently has a consensus price target of $35.00, suggesting a potential downside of 8.35%. Intercept Pharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 0.00%. Given Intercept Pharmaceuticals' higher possible upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).
2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 83.8% of Intercept Pharmaceuticals shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 6.2% of Intercept Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Intercept Pharmaceuticals received 1039 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 71.98% of users gave Intercept Pharmaceuticals an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
Summary
Intercept Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks.
Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calliditas Therapeutics AB (publ) Competitors List
Related Companies and Tools
